written on 21.05.2014

Second-line use, crowded market won't keep Takeda's Entyvio from blockbuster run


Takeda is finally over the hump with its inflammatory bowel disease drug Entyvio after safety questions threatened its approval. And while the drug will take a backseat to some of the market's heavyweights, some analysts say that won't stop it from hitting the blockbuster mark itself.